{'fraction_non_alphanumeric': 0.050177095631641085, 'fraction_numerical': 0.03128689492325856, 'mean_word_length': 5.141304347826087, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA‐restricted cytotoxic T cells

This study describes a simple method for long‐term establishment of human ovarian tumor lines and prediction of T‐cell epitopes that could be potentially useful in the generation of tumor‐specific cytotoxic T lymphocytes (CTLs). Nine ovarian tumor lines (INT.Ov) were generated from solid primary or metastatic tumors as well as from ascitic fluid. Notably all lines expressed HLA class I, intercellular adhesion molecule‐1 (ICAM‐1), polymorphic epithelial mucin (PEM) and cytokeratin (CK), but not HLA class II, B7.1 (CD80) or BAGE. While of the 9 lines tested 4 (INT.Ov1, 2, 5 and 6) expressed the folate receptor (FR‐α) and 6 (INT.Ov1, 2, 5, 6, 7 and 9) expressed the epidermal growth factor receptor (EGFR); MAGE‐1 and p185HER‐2/neu were only found in 2 lines (INT.Ov1 and 2) and GAGE‐1 expression in 1 line (INT.Ov2). The identification of class I MHC ligands and T‐cell epitopes within protein antigens was achieved by applying several theoretical methods including: 1) similarity or homology searches to MHCPEP; 2) BIMAS and 3) artificial neural network‐based predictions of proteins MAGE, GAGE, EGFR, p185HER‐2/neu and FR‐α expressed in INT.Ov lines. Because of the high frequency of expression of some of these proteins in ovarian cancer and the ability to determine HLA binding peptides efficiently, it is expected that after appropriate screening, a large cohort of ovarian cancer patients may become candidates to receive peptide‐based vaccines. Int. J. Cancer 73:143–150, 1997. © 1997 Wiley‐Liss, Inc.